The cysteinyl leukotrienes (cysLTs) and the peptide hormone endothelin (ET)-1 are potent bronchoconstrictor substances, and these mediators are also claimed to be implicated in the development of eosinophilic airway inflammation. Inthe present study, we have investigated the effect ofthe cysLT 1 receptor antagonist montelukastonthe developmentof an eosinophilic airwayinflammation 24 h afterintratracheal Sephadex (SDX) provocationinrats.Furthermore, the effect of montelukasttreatmentonthe generation of ET-1and other pro-inflammatory mediators has been studied.The inflammatory response was significantly reduced in the animals receiving SDX + montelukast compared to animals receiving solely SDX, as evaluated by a decrease in bronchoalveolar lavage fluid total cell count (10. , Po0.05), but not tumor necrosis factor-g or interleukin-8. In summary, treatment with the cysLT 1 receptor antagonist montelukast reduced the inflammatory response during development of an eosinophilic airway inflammation, possibly by inhibiting the release of pro-inflammatory mediators like ET-1 and IFN-g.r
INTRODUCTION
The cysteinyl leukotrienes (cysLTs) (LTC 4 /D 4 /E 4 ) and the peptide hormone endothelin (ET)-1are potent bronchoconstrictor substances (1^3). In addition to the bronchoconstrictor properties, these mediators seem to be implicated in the development of the eosinophilic airway in£ammation (4^6), which is a key feature of asthmatic airways. CysLTs have been shown to facilitate the migration of eosinophilic granulocytes in vitro (7) , and aerosolized cysLTs elicit in£ux of eosinophils into guinea pig airways in vivo (4) . Moreover, LTD 4 challenge has been reported to increase the percentage of eosinophils in sputum from asthmatic patients (8) .
The mechanism by which the cysLTs promote in£ux of in£ammatory cells has not been fully elucidated, but both a direct chemotactic e¡ect and recruitment of in£amma-tory cells by promoting the generation of other chemotactic mediators are possible mechanisms. During the development of an experimental eosinophilic airway in£ammation, Namovic et al. found that the in£ux of eosinophils into the airways was preceded by an increase in the level of cysLTs (9) . In comparable studies, also employing the model of Sephadex (SDX) provocation in rats, we have found a similar pattern with regard to ET-1 (10) .The rapid generation of both cysLTs and ET-1 is consistent with a hypothesis that these mediators may play important roles in the initiation of an eosinophilic airway in£ammation. In vitro studies have indicated that cysLTs might in fact stimulate the generation of the pro-in£am-matory mediator ET-1 (11) . Based on these ¢ndings, and studies indicating an anti-in£ammatory e¡ect of cysLT 1 -inhibitors on eosinophilic airway in£ammations (12,13), we hypothesized that cysLT 1 receptor antagonists may inhibit the generation of the pro-in£ammatory mediator ET-1.We have previously shown that inhibition of ET-1 activity reduces the in£ammatory response in an experimental eosinophilic airway in£ammation (5) .
During the last years, a number of LT-inhibitors have been developed. In clinical practice, the cysLT 1 receptor antagonists have gained most interest. An inhibitory effect on bronchoconstriction in asthmatics has been documented (14^17). Evidence for an anti-in£ammatory e¡ect in vivo is, however, limited.To study the anti-in£am-matory properties of the cysLT 1 receptor antagonist montelukast, we induced an eosinophilic airway in£am-mation in rats by intratracheal instillation of SDX. SDX is a dextran to which some rat strains are naturally sensitized, and bronchial or intratracheal provocation with these particles promotes an allergic eosinophilic in£am-mation (18) . One group of animals were treated with montelukast prior to the bronchial challenge, while the control group received saline. The e¡ect of montelukast treatment on the in£ammatory response in bronchoalveolar lavage £uid (BALF) and lung tissue was studied. In addition, the level of ET-1 in the BALF was measured, as was the concentration of the pro-in£ammatory mediators tumor necrosis factor (TNF)-a, interleukin (IL)-8 and interferon (IFN)-g, as we previously have observed an increase of these cytokines following SDX provocation of rats (19) .
METHODS

Experimental procedure
Male Wistar rats aged 12 weeks with an average weight of 320 g were used in the study. The experiments were approved by the Norwegian Ethics Committee for Animal Research, and performed according to the NIH guidelines for the use of experimental animals. SDX solution (5 mg ml À1 ) (G-200 Super¢ne, PharmaciaUpjohn, Uppsala, Sweden) dissolved in phosphate-bu¡ered saline (PBS) or PBS alone was given in a volume of 0.3 ml intratracheally to rats pretreated with either saline or montelukast (n = 12 in each group). A dose of 2 mg kg À1 body weight of the highly selective (20) cysLT 1 receptor antagonists montelukast (Merck Frosst, Canada Inc.) was chosen according to the manufacturer and administered orally 1h prior to provocation, and repeated after 8 and 16 h. Pilot studies revealed no e¡ect of montelukast treatment on the levels of ET-1, TNF-a, IL-8 and IFN-g in rats receivng intratracheal PBS instead of SDX. Bronchoalveolar lavage was performed by instillation of 3+2+2 ml PBS in the right stem bronchus, distal to the upper lobe, and the procedure was repeated on the left side. The lavage £uid was collected into prechilled tubes containing EDTA and kept on ice until centrifuged at 800 g for 10 min. at 41C.
Cell pro¢le in BALF and tissue in£ammation
Total cell recovery in BALF was counted in a Bˇrker hemocytometer, the pro¢le of the in£ammatory cells was evaluated on Di¡-Quick s (Baxter Diagnostics AG, Dˇ-dingen, Switzerland)-stained slides, and at least 400 nonepithelial cells were determined. Lung and airway tissues were embedded in para⁄n, and hematoxylin^eosin-stained histological sections (5 mm) were screened by two observers in a blinded manner.The in£ammatory response was assessed in tissues from all animals. Twenty regions were examined and the in£ammatory response graded as strong (score 3, 4300 in£ammatory cells), moderate (score 2, 75^300 in£ammatory cells), weak (score 1, o75 in£ammatory cells), or absent (score 0).
Biochemical analyses
ET-1 was determined using a radioimmuno-linked endothelin 1^21 speci¢c [ 125 I] assay system (RPA 555) from Amersham Pharmacia Biotech International, Cardi¡, U.K. Prior to ET-1analysis, samples were extracted in duplicate from 2 ml BALF. The BALF was added to acetic acid on Sep-Pak C18 cartridges (Millipore Corp., Milford, MA, U.S.A.), which were prewashed with ethanol and acetic acid. The extract was freeze dried and dissolved in borate bu¡er. The ET-1 assay has a limit of detection equivalent to 1.6 pg ml
À1
. For the samples with ET-1 concentrations below this limit, the values were set to 1.6 pg ml
. TNF-a was measured using a rat-speci¢c sandwich enzyme-linked immunosorbent assay (ELISA) (Factor-Test-X s , Genzyme Corporation, Cambridge, MA,U.S.A.).Values below the detection limit of this assay system (10 pg ml À1 ) were consequently set to 10 pg ml À1 . IFN-g was analyzed using a rat speci¢c ELISA (Cytoscreen s , BioSource International, Camarillo, CA, USA) and IL-8 (CINC/gro) was measured with Panatest s Rat IL-8 ELISA (Panapharm Laboratories, Kumamoto, Japan). All measurements were performed in duplicate, and values are given as means. For TNF-a, IL-8, and IFN-g assays, the BALF was concentrated ten-fold prior to analysis. The BALF was concentrated using Minicon cells (Amion Division, WR.Grace & Co., Beverly, MA, U.S.A.). Results are given as pg ml À1 unconcentrated BALF.
Statistical analysis
All values are expressed as means7SEM. Statistical analyses were performed using scienti¢c statistical software (SigmaStat version 2.0, Jandel Scienti¢c GmbH, Ekrath, Germany). The groups were compared using KruskalŴ allis one way analysis of variance on ranks, followed by a multiple comparisons procedure vs controls using Dunn's method. A P-value of less than 0.05 was considered statistically signi¢cant.
RESULTS
Cell pro¢le in BALF and tissue in£ammation
The SDX-induced increase in BALF total cell count was strongly inhibited by treatment with montelukast (10.371.2 vs controls; 18.571.8 Â10 4 ml
À1
, Po0.001) (Fig.  1(A) 
(B) and (C). No signi¢cant inhibition by montelukast could be observed with regard to the number of neutrophils and macrophages (Figs.1(D) and (E).
The histological evaluation of lung and airway sections following SDX-provocation of the animals revealed a pronounced in£ammation peribronchially and surrounding the SDX particles, dominated by eosinophils, neutrophils and macrophages. Treatment with montelukast resulted in a moderate decrease in the extent of in£am-mation in the tissues (in£ammatory score; 1.9270.08 vs 2.1470.05, Po0.05) (Fig. 2) .
Mediators in BALF
After 24 h, a signi¢cant increase in the concentration of both ET-1, IFN-g TNF-a, and IL-8 was observed in the SDX-treated animals, compared to controls (Fig. 3) . Treatment with montelukast prior to SDX provocation resulted in 30% decrease in the BALF level of ET-1 (Po0.05) (Fig. 3(A) ) and a 72% decrease in IFN-g (Po0.05) (Fig. 3(B) ), compared to the animals receiving solely SDX (Fig. 3) . The reduction in the concentration of TNF-a (30% and IL-8 (60%)) did not reach statistical signi¢cance (Figs 3(C) and (D) ).
DISCUSSION
The SDX-induced in£ammatory response was reduced by pretreatment of the animals with the cysLT 1 receptor blocker montelukast. We observed a decrease in BALF total cell count and in the number of eosinophils and lymphocytes, as well as a reduction in the degree of tissue in£ammation. In addition, treatment with montelukast signi¢cantly inhibited the SDX-induced increase in the concentration of the pro-in£ammatory mediators ET-1 and IFN-g. Eosinophils and lymphocytes are the two cell lines most strongly associated with bronchial asthma (21) . Therefore, it is interesting that the observed anti-in£ammatory e¡ect of montelukast seems to be related to a decrease in the number of both these cell types. With regard to eosinophils, Diamant et al. (17) did not observe an inhibitory e¡ect of montelukast on the in£ux of eosinophils into the airways of asthmatic patients after allergen challenge, however, that study was not speci¢cally designed or powered to evaluate sputum eosinophils. On the other hand, Pizzichini et al. (12) found a reduced percentage of eosinophils in induced sputum from asthma patients during montelukast treatment, and, in ovalbumin-sensitized rats, montelukast has also been shown to inhibit the in£ux of eosinophils into the airways (13) . The current study also examined the e¡ect of montelukast treatment on the number of BALF lymphocytes, since these cells also play an important role in the asthmatic airway in£ammation (21) .The inhibitory effect of montelukast on the in£ux of lymphocytes, in addition to a decrease in the number of eosinophils, is interesting. Using another cysLT 1 receptor antagonist, za¢rlukast, similar ¢ndings of a reduced number of lymphocytes have been shown following segmental allergen challenge in asthmatics (22) , but to our knowledge, reduction in the number of lymphocytes has not been reported after treatment with montelukast.
The mechanisms by which cysLT 1 receptor antagonists inhibit the in£ux of eosinophils and lymphocytes have not been elucidated. A direct chemotactic e¡ect of cysLTs on these cells may explain the rapid in£ux of leukocytes into the airways (8, 23) .Thus, blocking cysLT 1 receptors would inhibit that mechanism. On the other hand, LTs might promote in£ux of in£ammatory cells through the release of other pro-in£ammatory mediators. One study could show a blunted TNF-a release in BALF from allergen-challenged asthmatics pretreated with za¢rlukast (22) , and in vitro, pranlukast inhibits the IL-4 and IL-5 response from isolated mononuclear cells (24) . Finally, montelukast has recently been shown to reduce the number of IL-5 mRNA expressing cells after antigen stimulation in rats (13) .The present study demonstrates that montelukast signi¢cantly inhibited the SDXinduced ET-1 release in BALF. This has previously not been reported. During the development of an SDX-induced airway in£ammation, LTs in BALF are generated prior to the eosinophilic in£ammatory response (19) and immediately before the generation of ET-1 (19) . Since LTs seem to be generated before ET-1, and cysLTs have been shown to stimulate ET-1releasein vitro (11), it is possible that treatment with a cysLT 1 receptor antagonist might in£uence the generation of ET-1 and thereby reduce the chemotactic e¡ect of this peptide in vivo. This hypothesis is concordant with the current results, since treatment with the cysLT 1 receptor antagonist montelukast inhibits the release of ET-1, as well as the in£ux of eosinophils and lymphocytes. The pro-in£ammatory peptide ET-1 is associated with the development of airway in£ammation (5, 6, 10, 25) , and blocking of ET-receptors results in a decreased in£ux of both eosinophils and lymphocytes, a pattern similar to what is seen during treatment with montelukast. We do not believe that the reduced levels of ET-1is a result of a reduced number of in£ammatory cells after cysLT 1 receptor antagonism, since ET-1 is produced mainly in bronchial epithelial cells and in macrophages (10) . In previous studies, as well, we have observed changes in ET-1levels in BALF without alterations in the number of macrophages (5, 10) .
The IFN-g response in the present study was also inhibited by the treatment with montelukast, possibly due to reduction of the number of lymphocytes, since IFN-g is mainly produced by these cells (26) . Another possibility is that the IFN-g release is blunted due to decreased ET-1 concentration, since decreased levels of IFN-g has been demonstrated after treatment with an ET receptor antagonist in the SDX model (19) . Importantly, IFN-g upregulates monocyte and macrophage functions (27) and is also a potent activator of eosinophilic granulocytes (26) . The concentration of TNF-a, which may be synthesised from a variety of cells including airway epithelial cells, macrophages, mast cells and eosinophils (28), was not signi¢cantly reduced by montelukast treatment in the current study, neither was the concentration of IL-8. However, there was a clear trend in the direction of reduced levels of these cytokines in BALF, as well.
In conclusion, treatment with the cysLT 1 receptor antagonist montelukast signi¢cantly reduced the in£amma-tory response in an SDX-induced airway in£ammation in rats, as evaluated by a decrease in BALF total cell count, the number of eosinophils and lymphocytes, as well as the degree of tissue in£ammation. The generation of ET-1 and IFN-g in BALF was also reduced by montelukast treatment, indicating one possible mechanism for the anti-in£ammatory e¡ect of this cysLT 1 receptor antagonist. 
